Gyre Therapeutics Inc. (GYRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gyre Therapeutics Inc. (GYRE) has a cash flow conversion efficiency ratio of 0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.18 Million) by net assets ($136.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GYRE company net worth for the company's overall valuation and market capitalisation.
Gyre Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Gyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gyre Therapeutics Inc. ranked by their cash flow conversion efficiency. Explore GYRE operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BES Engineering Co
TW:2515
|
-0.007x |
|
Jiangsu Transimage Technology Co Ltd
SHE:002866
|
0.011x |
|
Ningbo Fangzheng Automobile Mould Co.Ltd.
SHE:300998
|
0.024x |
|
LG Chem Ltd
KO:051915
|
0.053x |
|
Hypoport SE
XETRA:HYQ
|
0.012x |
|
Echo Investment SA
WAR:ECH
|
0.140x |
|
Ricegrowers Ltd
AU:SGLLV
|
0.122x |
|
Allied Supreme Corp
TW:4770
|
0.006x |
Annual Cash Flow Conversion Efficiency for Gyre Therapeutics Inc. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Gyre Therapeutics Inc. from 2004 to 2025. View current stock price of Gyre Therapeutics Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $142.28 Million | $1.01 Million | 0.007x | +119.18% |
| 2024-12-31 | $98.40 Million | $-3.64 Million | -0.037x | -101.99% |
| 2023-12-31 | $13.95 Million | $25.89 Million | 1.856x | +1155.49% |
| 2022-12-31 | $72.22 Million | $10.68 Million | 0.148x | +107.25% |
| 2021-12-31 | $41.09 Million | $-83.75 Million | -2.038x | -181.68% |
| 2020-12-31 | $76.07 Million | $-55.05 Million | -0.724x | -13.39% |
| 2019-12-31 | $68.34 Million | $-43.61 Million | -0.638x | -168.10% |
| 2018-12-31 | $119.94 Million | $-28.55 Million | -0.238x | +63.26% |
| 2017-12-31 | $30.77 Million | $-19.94 Million | -0.648x | +43.63% |
| 2016-12-31 | $16.07 Million | $-18.47 Million | -1.149x | -88.93% |
| 2015-12-31 | $31.43 Million | $-19.12 Million | -0.608x | -92.45% |
| 2014-12-31 | $109.08 Million | $-34.48 Million | -0.316x | -4.78% |
| 2013-12-31 | $134.61 Million | $-40.61 Million | -0.302x | +17.38% |
| 2012-12-31 | $175.91 Million | $-64.24 Million | -0.365x | +23.98% |
| 2011-12-31 | $174.29 Million | $-83.72 Million | -0.480x | -131.90% |
| 2010-12-31 | $91.85 Million | $138.30 Million | 1.506x | +528.01% |
| 2009-12-31 | $68.99 Million | $-24.27 Million | -0.352x | +28.58% |
| 2008-12-31 | $57.37 Million | $-28.26 Million | -0.493x | -202.30% |
| 2007-12-31 | $51.58 Million | $24.84 Million | 0.482x | +416.38% |
| 2006-12-31 | $65.00 Million | $-9.89 Million | -0.152x | -194.22% |
| 2005-12-31 | $-162.48 Million | $-26.25 Million | 0.162x | -20.66% |
| 2004-12-31 | $-122.97 Million | $-25.04 Million | 0.204x | -- |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more